Johnson & Johnson Innovative Medicine Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Johnson & Johnson Innovative Medicine and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 40000 Johnson & Johnson Innovative Medicine employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Johnson & Johnson Innovative Medicine has purchased the following applications: Clario eCOA Clinical Trials for Clinical Trial Management in 2022 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Johnson & Johnson Innovative Medicine is running and its propensity to invest more and deepen its relationship with Clario or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Johnson & Johnson Innovative Medicine revenues, which have grown to $20.00 billion in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Johnson & Johnson Innovative Medicine intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.